These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 37016946)

  • 41. Clinical and genetic profiles of chinese pediatric patients with catecholaminergic polymorphic ventricular tachycardia.
    Yan Y; Tang L; Wang X; Zhou K; Hu F; Duan H; Liu X; Hua Y; Wang C
    Orphanet J Rare Dis; 2023 Dec; 18(1):380. PubMed ID: 38053087
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Repeatability of ventricular arrhythmia characteristics on the exercise-stress test in RYR2-mediated catecholaminergic polymorphic ventricular tachycardia.
    Peltenburg PJ; Pultoo SNJ; Tobert KE; Bos JM; Lieve KVV; Tanck M; Clur SB; Blom NA; Ackerman MJ; Wilde AAM; van der Werf C
    Europace; 2023 Feb; 25(2):619-626. PubMed ID: 36369981
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Characterization of a novel mutation in the cardiac ryanodine receptor that results in catecholaminergic polymorphic ventricular tachycardia.
    Jiang D; Jones PP; Davis DR; Gow R; Green MS; Birnie DH; Chen SR; Gollob MH
    Channels (Austin); 2010; 4(4):302-10. PubMed ID: 20676041
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Provocation Testing and Therapeutic Response in a Newly Described Channelopathy: RyR2 Calcium Release Deficiency Syndrome.
    Ormerod JOM; Ormondroyd E; Li Y; Taylor J; Wei J; Guo W; Wang R; Sarton CNS; McGuire K; Dreau HMP; Taylor JC; Ginks MR; Rajappan K; Chen SRW; Watkins H
    Circ Genom Precis Med; 2022 Feb; 15(1):e003589. PubMed ID: 34949103
    [TBL] [Abstract][Full Text] [Related]  

  • 45. S4153R is a gain-of-function mutation in the cardiac Ca(2+) release channel ryanodine receptor associated with catecholaminergic polymorphic ventricular tachycardia and paroxysmal atrial fibrillation.
    Zhabyeyev P; Hiess F; Wang R; Liu Y; Wayne Chen SR; Oudit GY
    Can J Cardiol; 2013 Aug; 29(8):993-6. PubMed ID: 23498838
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Prevention of ventricular arrhythmia and calcium dysregulation in a catecholaminergic polymorphic ventricular tachycardia mouse model carrying calsequestrin-2 mutation.
    Alcalai R; Wakimoto H; Arad M; Planer D; Konno T; Wang L; Seidman JG; Seidman CE; Berul CI
    J Cardiovasc Electrophysiol; 2011 Mar; 22(3):316-24. PubMed ID: 20807279
    [TBL] [Abstract][Full Text] [Related]  

  • 47. A novel RYR2 loss-of-function mutation (I4855M) is associated with left ventricular non-compaction and atypical catecholaminergic polymorphic ventricular tachycardia.
    Roston TM; Guo W; Krahn AD; Wang R; Van Petegem F; Sanatani S; Chen SR; Lehman A
    J Electrocardiol; 2017; 50(2):227-233. PubMed ID: 27646203
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Clinical characteristics and mutational analysis of the RyR2 gene in seven Czech families with catecholaminergic polymorphic ventricular tachycardia.
    Andrsova I; Valaskova I; Kubus P; Vit P; Gaillyova R; Kadlecova J; Manouskova L; Novotny T
    Pacing Clin Electrophysiol; 2012 Jul; 35(7):798-803. PubMed ID: 22519458
    [TBL] [Abstract][Full Text] [Related]  

  • 49. An International Multicenter Cohort Study on β-Blockers for the Treatment of Symptomatic Children With Catecholaminergic Polymorphic Ventricular Tachycardia.
    Peltenburg PJ; Kallas D; Bos JM; Lieve KVV; Franciosi S; Roston TM; Denjoy I; Sorensen KB; Ohno S; Roses-Noguer F; Aiba T; Maltret A; LaPage MJ; Atallah J; Giudicessi JR; Clur SB; Blom NA; Tanck M; Extramiana F; Kato K; Barc J; Borggrefe M; Behr ER; Sarquella-Brugada G; Tfelt-Hansen J; Zorio E; Swan H; Kammeraad JAE; Krahn AD; Davis A; Sacher F; Schwartz PJ; Roberts JD; Skinner JR; van den Berg MP; Kannankeril PJ; Drago F; Robyns T; Haugaa K; Tavacova T; Semsarian C; Till J; Probst V; Brugada R; Shimizu W; Horie M; Leenhardt A; Ackerman MJ; Sanatani S; van der Werf C; Wilde AAM
    Circulation; 2022 Feb; 145(5):333-344. PubMed ID: 34874747
    [TBL] [Abstract][Full Text] [Related]  

  • 50. A novel heterozygous mutation in cardiac calsequestrin causes autosomal dominant catecholaminergic polymorphic ventricular tachycardia.
    Gray B; Bagnall RD; Lam L; Ingles J; Turner C; Haan E; Davis A; Yang PC; Clancy CE; Sy RW; Semsarian C
    Heart Rhythm; 2016 Aug; 13(8):1652-60. PubMed ID: 27157848
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Ventricular arrhythmia suppression with ivabradine in a patient with catecholaminergic polymorphic ventricular tachycardia refractory to nadolol, flecainide, and sympathectomy.
    Kohli U; Aziz Z; Beaser AD; Nayak HM
    Pacing Clin Electrophysiol; 2020 May; 43(5):527-533. PubMed ID: 32259298
    [TBL] [Abstract][Full Text] [Related]  

  • 52. RYR2-ryanodinopathies: from calcium overload to calcium deficiency.
    Steinberg C; Roston TM; van der Werf C; Sanatani S; Chen SRW; Wilde AAM; Krahn AD
    Europace; 2023 Jun; 25(6):. PubMed ID: 37387319
    [TBL] [Abstract][Full Text] [Related]  

  • 53. A Focus on Pharmacological Management of Catecholaminergic Polymorphic Ventricular Tachycardia.
    Claudio B; Alice M; Daniel S
    Mini Rev Med Chem; 2018; 18(6):476-482. PubMed ID: 28685702
    [TBL] [Abstract][Full Text] [Related]  

  • 54. In silico prediction of drug therapy in catecholaminergic polymorphic ventricular tachycardia.
    Yang PC; Moreno JD; Miyake CY; Vaughn-Behrens SB; Jeng MT; Grandi E; Wehrens XH; Noskov SY; Clancy CE
    J Physiol; 2016 Feb; 594(3):567-93. PubMed ID: 26515697
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Molecular and tissue mechanisms of catecholaminergic polymorphic ventricular tachycardia.
    Wleklinski MJ; Kannankeril PJ; Knollmann BC
    J Physiol; 2020 Jul; 598(14):2817-2834. PubMed ID: 32115705
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Deadly proposal: a case of catecholaminergic polymorphic ventricular tachycardia.
    Heiner JD; Bullard-Berent JH; Inbar S
    Pediatr Emerg Care; 2011 Nov; 27(11):1065-8. PubMed ID: 22068070
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Cardiac arrest in a mother and daughter and the identification of a novel RYR2 variant, predisposing to low penetrant catecholaminergic polymorphic ventricular tachycardia in a four-generation Canadian family.
    Tung M; Van Petegem F; Lauson S; Collier A; Hodgkinson K; Fernandez B; Connors S; Leather R; Sanatani S; Arbour L
    Mol Genet Genomic Med; 2020 Apr; 8(4):e1151. PubMed ID: 31994352
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Flecainide exerts paradoxical effects on sodium currents and atrial arrhythmia in murine RyR2-P2328S hearts.
    Salvage SC; King JH; Chandrasekharan KH; Jafferji DI; Guzadhur L; Matthews HR; Huang CL; Fraser JA
    Acta Physiol (Oxf); 2015 Jul; 214(3):361-75. PubMed ID: 25850710
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Slowed depolarization and irregular repolarization in catecholaminergic polymorphic ventricular tachycardia: a study from cellular Ca2+ transients and action potentials to clinical monophasic action potentials and electrocardiography.
    Paavola J; Väänänen H; Larsson K; Penttinen K; Toivonen L; Kontula K; Laine M; Aalto-Setälä K; Swan H; Viitasalo M
    Europace; 2016 Oct; 18(10):1599-1607. PubMed ID: 26705554
    [TBL] [Abstract][Full Text] [Related]  

  • 60. A novel cardiac ryanodine receptor gene (RyR2) mutation in an athlete with aborted sudden cardiac death: a case of adult-onset catecholaminergic polymorphic ventricular tachycardia.
    Arakawa J; Hamabe A; Aiba T; Nagai T; Yoshida M; Touya T; Ishigami N; Hisadome H; Katsushika S; Tabata H; Miyamoto Y; Shimizu W
    Heart Vessels; 2015 Nov; 30(6):835-40. PubMed ID: 25092222
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.